EFTA01100382.pdf

BioReference PRELIMINARY LABORATORIES EPSTEIN, JEFFREY Specimen ID: 100820998 P DOB: Age: 62 y Sex: M Date Of Report: 10/29/2015 09:10 D A U/FL: Bed: Date Collected: 10/27/2015 16:44 T Rm: Date Received: 10/27/2015 22:29 C I Patient ID: T NEW YORK, NY 10028 E Address: R Acct #: (C1720) P: 1 North America Eastern Time Notes: NON FASTING CLINICAL REPORT f (May not contain all abnormal results; narrative results may not have Clinical Abnormalities Summary: abnormal flags. Please review entire report.) Cholesterol 210 HI Triglycerides 348 HI HDL CHOL., DIRECT 29 LO HDL as % of Cholesterol 14 * LDL/HDL Ratio 3.83 HI UDL Cholesterol 111 HI VLDL, CALCULATED 70 HI PT 10.0 LO INTR.NORM.RATIO(INR) 0.92 LO Blood, Urine SMALL * TESTOSTERONE, TOT.,S. 112.3 LO FREE TESTOSTERONE 29.82 LO PROLACTIN, SERUM 3.4 LO Hemoglobin A1C 5.9 HI * CHEMISTRY * Test Result Abnormal 'e erence In s 'rev ous •esu ra e Total Protein 7.1 5.9-8.4 g/dL Albumin 4.6 3.5-5.2 g/dL Globulin 2.5 1.7-3.7 g/dL AA Ratio 1.8 1.1-2.9 Glucose 95 70-99 mg/dL Sodium 135 133-145 mmol/L Potassium 4.2 3.3-5.3 mmol/L Chloride 96 96-108 mmol/L C02 26 22-29 mmol/L BUN 21 8-23 mg/dL Creatinine 1.03 0.80-1.30 mg/dL e-GFR 77 >orw60 mL/min e-GFR, African American 89 >or=60 mL/min BUN/Creat Ratio 20.4 10.0-28.0 Calcium 9.7 8.6-10.4 mg/dL Uric Acid 6.2 3.4-8.5 mg/dL Iron 57 45-160 ug/cil Bilirubin, Total 0.5 <1.2 mg/dL LD 177 135-225 U/L Alk Phos 62 40-156 U/L AST 23 <40 U/L PHOSPHORUS 3.3 2.7-4.5 mg/dL ALT 25 <41 U/L GGTP 15 10-71 U/L -* CARDIOVASCULAR/LIPIDS *-- Cholesterol 210 HI <200 mg/dL Triglycerides 348 HI <150 mg/dL BioReference Laboratories, Inc. JamesiallebbeegerILD. Page 1 of 5 481 Edward H. Ross Dr I Elmwood Park. NJ 07407 I Laboratory Director Printed 11/02/2015 12:27 EFTA01100382 BioReference PRELIMINARY LABORATORIES FISCH, HARRY EPSTEIN, JEFFREY Specimen ID: 100820998 p DOB: Age: 62 y Sex: M Date Of Report: 10/29/2015 09:10 D 1720 - HARRY FISCH, M.D. A U/FL: Bed: Date Collected: 10/27/2015 16:44 0 T Rm: Date Received: 10/27/2015 22:29 C I Patient ID: T NEW YORK, NY 10028 E Address: N R Acct #: (C1720) S1 T P: P: 1 North America Eastern Time CLINICAL REPORT Test Result Abnormal Reference Units Previous Result Date HDL CHOL., DIRECT 29 LO >40 mg/dL HDL as % of Cholesterol 14 , >14 % Evaluation: ABOVE AVG.(MODERATE RISK) Chol/HDL Ratio 7.2 <7.4 Evaluation: AVERAGE RISK LDL/HDL Ratio 3.83 HI <3.56 LDL Cholesterol 111 HI <100 mg/dL VLDL, CALCULATED 70 HI 7-32 mg/dL * HEMATOLOGY * WBC 6.33 3.40-11.80 x10(3)/uL RBC 5.01 4.20-5.90 x10(6)/uL HGB 14.6 12.3-17.0 gm/dL HCT 41.9 39.3-52.5 % MCV 83.6 80.0-100.0 fL MCH 29.1 25.0-34.1 pg MCHC 34.8 29.0-35.0 gm/dL RDW 14.4 10.9-16.9 % POLYS 51.1 36.0-78.0 % LYMPHS 37.1 12.0-48.0 % MONOS 5.8 0.0-13.0 EOS 5.4 0.0-8.0 % BASOS 0.6 0.0-2.0 % IMMATURE GRANULOCYTES 0.0 0.0-1.6 % Platelet Count 257 144-400 x10(3)/ut MPV 9.0 8.2-11.9 fL PT 10.0 LO 10.3-12.8 sec INTR.NORM.RATIO(INR) 0.92 LO 2.00-3.00 CLINICAL INDICATIONS FOR INR USE Reference Range Prophylaxis or treatment of venous thrombosis, 2.00-3.00 systemic embolization, and pulmonary embolus High-risk patients with mechanical heart valves 2.50-3.50 Normal Non-Medicated patients 0.87-1.19 NOTE: INR values below 2.00 for patients on warfarin therapy would be considered sub-therapeutic for the above conditions. PTT 27.6 23.6-31.6 sec I BioReference Laboratories, Inc. James Weisberger M.D. Page 2 of 5 481 Edward H. Ross Dr I Elmwood Park. NJ 07407 Laboratory Director Printed 11/02/2015 12:27 EFTA01100383 BioReference PRELIMINARY LABORATORIES FISCH, HARRY EPSTEIN, JEFFREY Specimen ID: 100820998 P DOB: Age: 62 y Sex: M Date Of Report: 10/29/2015 09:10 D A U/FL: Bed: Date Collected: 10/27/2015 16:44 0 C1720 - HARRY FISCH, M.D. T Rm: Date Received: 10/27/2015 22:29 C I Patient ID: 0 NEW YORK, NY 10028 E Address: N R Acct #: (C1720) S1 T P: P: 1 North America Eastern Time CLINICAL REPORT Test Result Abnormal Reference m Units Previous Result Date * URINALYSIS * Color YELLOW YELLOW, STRAW, AMBER Character CLEAR CLEAR Specific Gravity URN 1.023 1.003 - 1.030 pH Urine 5.0 5.0 - 8.0 Protein, Urine NEGATIVE NEGATIVE Glucose, Urine NEGATIVE NEGATIVE Ketone, Urine NEGATIVE NEGATIVE Urobilinogen Urine 0.2 0.2 - 1.0 Units Bilirubin, Urine NEGATIVE NEGATIVE Blood, Urine SMALL * NEGATIVE Nitrites Urine NEGATIVE NEGATIVE Leukocyte Esterase NEGATIVE NEGATIVE Crystals Urine NONE NONE Crystal Amt. Urine NONE NONE W8C, Urine 0-4 0-4 PER HPF RBC, Urine NONE SEEN NONE SEEN PER HPF Epithelial Cells, Ur NONE FEW Cast, Hyaline, Urine 0-4 0-4 PER LPF Cast, Granular, Urin NONE SEEN 0-1 PER LPF Cast, RBC, Urine NONE SEEN 0-1 PER LPF Bacteria, Urine NONE FEW ' MICROBIOLOGY * CULTURE, URINE <10,000 NO GROWTH CFU/ML (U... <10,000 CFU/ML (USUALLY CONSIDERED INSIGNIFICANT GROWTH) SOURCE: URINE ' MISCELLANEOUS ' TSH 2.060 0.178-4.530 uIU/mL THYROXINE(T4) 7.5 4.9-12.9 ug/dL T3 UPTAKE (T3U) 29.1 24.3-39.0 X THYROXINE, FREE (FT4) 1.06 0.80-1.73 ng/dL FREE T4 INDEX 2.2 1.5-3.8 T3 (THYRONINE), TOTAL 129 72-180 ng/dL PSA Total 0.87 <4.00 ng/mL NOTE: The PSA assay should not be the only test used for diagnostic purposes. Additional evaluation using DRE, ultrasound, TUR or similar procedures may be used for this purpose. Predictions of disease recurrence should not be BioReference Laboratories, Inc. James Weisberger M.D. Page 3 of 5 481 Edward H. Ross Dr I Elmwood Park. NJ 07407 Laboratory Director printed 11/02/2015 12:27 EFTA01100384 BioReference PRELIMINARY LABORATORIES EPSTEIN, JEFFREY 1 Specimen ID: 100820998 I P DOB: Age: 62 y Sex: M Date Of Report: 10/29/2015 09:10 D A U/FL: Bed: Date Collected: 10/27/2015 16:44 0 T Rm: Date Received: 10/27/2015 22:29 C I Patient ID: T NEW YORK, NY 10028 E Address: R Acct #: (C1720) T P: P: North Americo Eastern Time CLINICAL REPORT Test Result Abnormal Reference Units I Previous Result' Date based solely upon values obtained from serial P5A values obtained on the patient. NOTE: Values obtained with different assay methods or kits cannot be used interchangeably. NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics). PSA, FREE 0.31 Not Estab. ng/mL I NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. Values obtained with different assay methods or kits cannot be used interchangeably. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics). % FREE PSA 36 See Below % I FREE PSA RISK ASSESSMENT The probability of prostate cancer for men with non-suspicious DRE results, by age group, using PSA values between 4.000 and 10.000 ng/mL and percent FREE PSA values is summarized in the table below: PROBABILITY OF CANCER* %free PSA (50-59 yrs) (60-69 yrs) (>or.70 yrs) <or.10 49.2% 57.5% 64.5% 11-18 26.9% 33.9% 40.8% 19-25 18.3% 23.9% 29.7% >25 9.1% 12.2% 15.8% *probability of finding prostate cancer by needle biopsy NOTE: Calculation of percent FREE PSA may not be possible when the value for TOTAL PSA is in the low normal range. These guidelines are for assays performed using the Roche E170 immunoassay system.(02/2012;v5) TESTOSTERONE, TOT.,S. 112.3 LO 193.0-740.0 ng/dL TESTOSTERONE, BIOAVAIL. 74.6 72.0-460.0 ng/dL SEX HORM.BIND.GLOB. 14 10-57 nmol/L FREE TESTOSTERONE 29.82 LO 30.00-150.00 pg/mL LH 3.7 1.7-8.6 mIU/mL FSH 4.0 1.5-12.4 mIU/mL PROLACTIN, SERUM 3.4 LO 4.0-15.2 ng/mL ESTRADIOL 16.00 7.02-49.06 pg/mL FIBRINOGEN 362 176-441 mg/dL Hemoglobin AbC 5.9 HI <5.7 % HEMOGLOBIN Aic AND eAG REFERENCE RANGES A1c(%) DIABETES CATEGORY* <5.7 Normal (non-diabetic) 5.7-6.4 Increased risk .._._._.__. _.._of diabetes BioReference Laboratories, Inc. JaniesPhMsbergerfA.D. Page 4 of 5 481 Edward H. Ross Dr I Elmwood Park. NJ 07407 I Laboratory Director Printed 11/02/2015 12:27 EFTA01100385 BioReference PRELIMINARY LABORATORIES EPSTEIN, JEFFREY Specimen ID: 100820998 P DOB: Age: 62 y Sex: M Date Of Report: 10/29/2015 09:10 D A U/FL: Bed: Date Collected: 10/27/2015 16:44 0 T Rm: Date Received: 10/27/2015 22:29 C I Patient ID: T NEW YORK, NY 10028 Address: R Acct #: (C1720) P: P: : North Americo Eastern Time CLINICAL REPORT Test Result Abnormal Reference Units [Previous Result' Date .>6.5 Consistent with diabetes A1c(%) eAG(ESTIMATED AVERAGE PLASMA GLUCOSE)(mg/dL) 6 126 7 154 8 183 9 212 10 240 11 269 12 298 *recommended ranges-American Diabetes Association(2010) NOTE: Hemolysis, rare hemoglobin variants and thalassemia major may affect glycemic results. DIHYDROTESTOSTERONE TO FOLLOW SEE REPORT BioReference Laboratories, Inc. James Weisberger M.D. Page 5 of 5 481 Edward H. Ross Dr I Elmwood Park, NJ 07407 Laboratory Director Printed 11/02/2015 12:27 EFTA01100386